Using morphoproteomic analysis in conjunction with the genomic characterization of the patient's tumor as PAX3-FKHR (FOXO1) subtype and data from xenograft testing of his tumor in the context of data mining of the National Library of Medicine's MEDLINE data base, we have further characterized the biology of this subtype and provide genomic, proteomic and pharmacogenomics correlates to targeted therapies. The gene discussed is FOXO1; the disease is neoplasm.